Array BioPharma Lung-Cancer Treatment Misses Primary Goals – Wall Street Journal


Array BioPharma Lung-Cancer Treatment Misses Primary Goals
Wall Street Journal
Array BioPharma Inc.'s (ARRY) treatment for a certain type of metastatic nonsmall cell lung cancer with a certain type of mutation failed to meet its primary endpoint in a Phase II study in combination with chemotherapy. The biopharmaceutical company's
Topline Results: A Randomized Phase 2 Study of Selumetinib in Patients with MarketWatch (press release)

all 16 news articles »

Cancer – Google News